Sun Pharma shares in focus ahead of Q2 results today
Sun Pharma will be in focus as the company will announce its results for the July-September 2024 period later today.
Analysts expect the company to report healthy revenue growth during the second quarter, driven by the domestic business with favourable seasonality and growing volumes.
Revenue from operations is likely to jump 10% year-on-year, according to an average estimate of four brokerages. Meanwhile, net profit for the quarter is seen rising up to 25% year-on-year.
Analysts are building in $482 million US sales in 2QFY25, primarily due to higher specialty sales, tad higher gRevlimid sales, as well as continued ramp-up in gPentasa supplies from Mohali.
Gross margins are likely to improve on a sequential basis, while EBITDA margins may drop due to higher research and development (R&D) spending.
Stock Trading
RSI Trading Techniques: Mastering the RSI Indicator
By — Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert
Stock Trading
Futures Trading Made Easy: Future & Options Trading Course
By — Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant
Stock Trading
Point & Figure Chart Mastery: A Comprehensive Trading Guide
By — Mukta Dhamankar, Full Time Trader, 15 Years Experience, Instructor
Stock Trading
Stock Valuation Made Easy
By — Rounak Gouti, Investment commentary writer, Experience in equity research
Stock Trading
A2Z of Stock Market for Beginners: Stock Market Course For Beginners
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
ROC Made Easy: Master Course for
